 There are federal moves in the works to encourage and improve racial diversity with drug clinical trials in the U.S. The FDA is now recommending steps to expand drug and medicine device trials in efforts to prioritize characteristics of the patient population they aim to treat. The agency's suggestions to researchers include drafts on how to set goals for study enrollment separated by age group, ethnicity, sex, and race, and describe how they intend to meet those goals.